丙戊酸钠与既往缺血性卒中或TIA后卒中风险降低相关
SVA组复发卒中率更低(17/168 vs 105/530,P=0.002),校正混杂后SVA仍与卒中风险降低相关(HR=0.44,95%CI 0.3-0.7,P=0.002),提示SVA可能降低复发卒中风险,但不能排除残余混杂。
要点
- SVA组复发卒中率低于其他抗癫痫药组(17/168 vs 105/530,P=0.002)。
- 校正混杂后SVA与卒中风险降低独立相关(HR=0.44,95%CI 0.3-0.7)。
- SVA与非SVA患者比较结果相似(HR=0.47,95%CI 0.29-0.77,P=0.003)。
核心结论
- SVA暴露可能与复发卒中风险降低相关。
- 不能排除研究设计中的残余混杂。
- 结果支持HDAC9在缺血性卒中发病中重要,其抑制值得评估用于预防复发。
研究设计与样本
- 汇总3项前瞻性研究:South London Stroke Register、The Vitamins to Prevent Stroke Study、Oxford Vascular Study。
- 纳入既往卒中或TIA并长期随访的患者。
- SVA组与其他抗癫痫药组比较,采用生存分析和Cox回归。
主要发现
- SVA组复发卒中17/168,其他抗癫痫药组105/530,log-rank P=0.002。
- Cox回归校正潜在混杂后,SVA与卒中减少相关(HR=0.44,95%CI 0.3-0.7,P=0.002)。
- SVA组与所有未用SVA者比较,Cox回归HR=0.47,95%CI 0.29-0.77,P=0.003。
临床怎么用
- 提示SVA可能作为缺血性卒中二级预防的候选药物,但需进一步研究验证。
- 目前证据不足以支持临床常规使用SVA预防卒中复发。
局限性
- 研究设计不能排除残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: A variant in the histone deacetylase 9 (HDAC9) gene is associated with large artery stroke. Therefore, inhibiting HDAC9 might offer a novel secondary preventative treatment for ischemic stroke. The antiepileptic drug sodium valproate (SVA) is a nonspecific inhibitor of HDAC9. We tested whether SVA therapy given after ischemic stroke was associated with reduced recurrent stroke rate. METHODS: Data were pooled from 3 prospective studies recruiting patients with previous stroke or transient ischemic attack and long-term follow-up: the South London Stroke Register, The Vitamins to Prevent Stroke Study, and the Oxford Vascular Study. Patients receiving SVA were compared with patients who received antiepileptic drugs other than SVA using survival analysis and Cox Regression. RESULTS: A total of 11 949 patients with confirmed ischemic event were included. Recurrent stroke rate was lower in patient taking SVA (17 of 168) than other antiepileptic drugs (105 of 530; log-rank survival analysis P=0.002). On Cox regression, controlling for potential cofounders, SVA remained associated with reduced stroke (hazard ratio=0.44; 95% confidence interval: 0.3-0.7; P=0.002). A similar result was obtained when patients taking SVA were compared with all cases not taking SVA (Cox regression, hazard ratio=0.47; 95% confidence interval: 0.29-0.77; P=0.003). CONCLUSIONS: These results suggest that exposure to SVA, an inhibitor of HDAC, may be associated with a lower recurrent stroke risk although we cannot exclude residual confounding in this study design. This supports the hypothesis that HDAC9 is important in the ischemic stroke pathogenesis and that its inhibition, by SVA or a more specific HDAC9 inhibitor, is worthy of evaluation as a treatment to prevent recurrent ischemic stroke.
引用
- Brookes RL, Crichton S, Wolfe CDA, et al. Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack. Stroke. 2017. PMID: 29247141. doi:10.1161/STROKEAHA.117.016674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。